Table 2.
Correlation between CEP55 expression and clinicopathologic features of EOC
| Characteristics | Total | CEP55 | Chi-squared test P value |
Fisher’s exact test P value |
||
|---|---|---|---|---|---|---|
| No or weak expression | Moderate or strong expression | |||||
| Age (years) | <53 | 111 | 59 (27.7) | 52 (24.4) | 0.911 | 1.000 |
| ≥53 | 102 | 55 (25.8) | 47 (22.1) | |||
| FIGO stage | I | 59 | 56 (26.3) | 3 (1.4) | <0.001 | – |
| II | 36 | 29 (13.6) | 7 (3.3) | |||
| III | 100 | 27 (12.7) | 73 (34.3) | |||
| IV | 18 | 2 (0.9) | 16 (7.5) | |||
| Lymph node metastasis | Absent | 173 | 107 (50.2) | 66 (31.0) | <0.001 | <0.001 |
| Present | 40 | 7 (3.3) | 33 (15.5) | |||
| Histological type | Serous cell carcinoma | 154 | 82 (38.5) | 72 (33.8) | 0.143 | – |
| Mucous cell carcinoma | 44 | 20 (9.4) | 24 (11.3) | |||
| Endometrial carcinoma | 9 | 7 (3.3) | 2 (0.9) | |||
| Clear cell carcinoma | 6 | 5 (2.3) | 1 (0.5) | |||
| Intraperitoneal metastasis | No | 110 | 83 (39.0) | 27 (12.7) | <0.001 | <0.001 |
| Yes | 103 | 31 (14.5) | 72 (33.8) | |||
| Tumor recurrence | No | 121 | 105 (49.3) | 16 (7.5) | <0.001 | <0.001 |
| Yes | 92 | 9 (4.2) | 83 (39.0) | |||
| Vital status (at last follow-up) | No | 111 | 95 (44.6) | 16 (7.5) | <0.001 | <0.001 |
| Yes | 102 | 19 (8.9) | 83 (39.0) | |||
| Differentiation grade | G1/G2 | 128 | 82 (38.5) | 46 (21.6) | <0.001 | <0.001 |
| G3 | 85 | 32 (15.0) | 53 (24.9) | |||
| Residual tumor | ≤1 | 150 | 92 (43.2) | 58 (27.2) | <0.001 | 0.001 |
| Size (cm) | >1 | 63 | 22 (10.3) | 41 (19.3) | ||
| Neoadjuvant chemotherapy | No | 158 | 96 (45.1) | 62 (29.1) | <0.001 | <0.001 |
| Yes | 55 | 18 (8.4) | 37 (17.4) | |||
| Postoperative chemotherapy | No | 22 | 11 (5.2) | 11 (5.2) | 0.727 | 0.823 |
| Yes | 191 | 103 (48.3) | 88 (41.3) | |||
| HIPEC | No | 142 | 78 (36.6) | 64 (30.1) | 0.560 | 0.564 |
| Yes | 71 | 36 (16.9) | 35 (16.4) | |||
| Ascites see tumor cells (+) | No | 148 | 87 (40.8) | 61 (28.6) | 0.020 | 0.025 |
| Yes | 65 | 27 (12.7) | 38 (17.8) | |||
| Cytoreductive surgery | No | 71 | 46 (21.6) | 24 (11.3) | 0.020 | 0.021 |
| Yes | 142 | 68 (31.9) | 74 (34.7) | |||
| CA125 (U/ml) | ≤35 | 14 | 10 (4.7) | 4 (1.9) | 0.165 | 0.267 |
| >35 | 197 | 103 (48.8) | 94 (44.6) | |||
| CA199 (U/ml) | ≤35 | 156 | 83 (39.3) | 73 (34.6) | 0.686 | 0.754 |
| >35 | 55 | 31 (14.7) | 24 (11.4) | |||
| CA153 (U/ml) | ≤25 | 82 | 59 (29.1) | 23 (11.3) | <0.001 | <0.001 |
| >25 | 121 | 50 (24.6) | 71 (35.0) | |||
| NSE (U/ml) | ≤15.2 | 46 | 27 (18.5) | 19 (13.0) | 0.387 | 0.475 |
| >15.2 | 100 | 51 (34.9) | 49 (33.6) | |||
| CEA (U/ml) | ≤5.0 | 67 | 41 (51.3) | 26 (32.5) | 0.621 | 0.759 |
| >5.0 | 13 | 7 (8.7) | 6 (7.5) | |||
| β-HCG (U/ml) | ≤3.0 | 65 | 35 (38.5) | 30 (33.0) | 0.315 | 0.356 |
| >3.0 | 26 | 17 (18.7) | 9 (9.9) | |||
| CA724 (U/ml) | ≤5.3 | 5 | 1 (7.7) | 4 (30.8) | 0.506 | 1.000 |
| >5.3 | 8 | 3 (23.1) | 5 (38.5) | |||
HIPEC hyperthermic intraperitoneal chemotherapy, FIGO International Federation of Gynecology and Obstetrics